Cargando…
Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy
Soft-tissue sarcomas (STS), with over 100 different histologic subtypes, are rare tumors that account for 1% of all adult malignancies. Immune checkpoint inhibitors (ICIs) display certain benefits in some subtypes, especially in undifferentiated pleomorphic sarcoma (UPS), alveolar soft part sarcoma...
Autores principales: | Li, Yong, Liu, Yihong, Qu, Yanchun, Chen, Xian, Qu, Xin, Ye, Yongsong, Du, Xiaohua, Cheng, Ying, Xu, Mian, Zhang, Haibo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120574/ https://www.ncbi.nlm.nih.gov/pubmed/35603147 http://dx.doi.org/10.3389/fimmu.2022.832593 |
Ejemplares similares
-
Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review
por: Wu, Shugui, et al.
Publicado: (2023) -
Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023) -
Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
por: Fu, Yang, et al.
Publicado: (2022) -
Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report
por: Wu, Ying, et al.
Publicado: (2023) -
Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
por: Zan, Ning, et al.
Publicado: (2022)